# Intravenous MSC Therapy on Ischemia-Reperfusion Injury in Patients With Myocardial Infarction

> **NCT03533153** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 90 (estimated)

## Conditions studied

- Myocardial Infarction

## Interventions

- **BIOLOGICAL:** WJ-MSC cells implantation
- **DRUG:** CTSTMD PBS without WJ-MSC
- **DRUG:** Conventional drug therapy

## Key facts

- **NCT ID:** NCT03533153
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2023-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03533153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03533153, "Intravenous MSC Therapy on Ischemia-Reperfusion Injury in Patients With Myocardial Infarction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03533153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*